 Study FX2016-40 enrolled 447 patients in the United States who were randomized to either FCD105 foam, 3 minocycline foam, 0.3 adapalene foam, or vehicle foam. The Company has begun preparations to conduct an End of Phase 2 meeting with the FDA before the end of this year. FCD105 showed a highly statistically significant improvement compared to vehicle for the endpoints of 1 Investigators Global Assessment IGA treatment success IGA score 0 or 1 and at least a two-grade improvement from baseline and 2 absolute change from baseline in mean inflammatory counts at Week 12. 